Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 4/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.46 |
| ▸ | HTR2A | P28223 | 9/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487040 | 0.91 | HTR2A (0.45) | CARM1PRMT6SLC6A4HTR2AKCNH2 | |
| SCHEMBL3487536 | 0.87 | GCK (0.42) | CARM1PRMT6SLC6A4HTR2AKCNH2 | |
| SCHEMBL3488354 | 0.86 | MAPK14 (0.46) | SLC6A4HTR2A | |
| SCHEMBL3488332 | 0.85 | GCK (0.46) | CARM1PRMT6PTGER4PTGER2PPARG | |
| SCHEMBL3487235 | 0.83 | PPARG (0.39) | CARM1PRMT6SLC6A4PPARGPPARD | |
| SCHEMBL3487657 | 0.83 | GCK (0.50) | CARM1PRMT6 | |
| SCHEMBL3487488 | 0.82 | MAPK1 (0.45) | CARM1PRMT6SLC6A4HTR2AKCNH2 | |
| SCHEMBL3487480 | 0.82 | MAPK1 (0.45) | CARM1PRMT6SLC6A4HTR2AKCNH2 | |
| SCHEMBL3487565 | 0.81 | HTR2A (0.46) | CARM1PRMT6SLC6A4HTR2AKCNH2 | |
| SCHEMBL3487706 | 0.81 | PPARG (0.41) | CARM1PRMT6SLC6A4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138484-B1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2138484-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | PPARG, GPR119, PPARA | CARM1 1256/4885PRMT6 2335/4885SLC6A4 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.